To increase the anti-cancer efficacy of gefitinib and reduce side effects, we evaluated the combinatorial effect of peptide drug cilengitide with gefitinib on cell survival and TGF-β-mediated EMT in NSCLC cells. This evidence concerns the gene TGFB1 and cancer.